Harris Associates’s Celgene Corp CELG Stock Holding History

Harris Associates’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-10,516	Closed	-$903K	–	185
2014 Q2	$903K	Hold	10,516	–	–	﹤0.01%	147
2014 Q1	$734K	Hold	10,516	–	–	﹤0.01%	150
2013 Q4	$888K	Hold	10,516	–	–	﹤0.01%	151
2013 Q3	$810K	Hold	10,516	–	–	﹤0.01%	152
2013 Q2	$615K	Buy	+10,516	New	+$633K	﹤0.01%	164

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Harris Associates's CELG Position: Q3 2014 in Review

Harris Associates sold out of Celgene Corp (CELG) in Q3 2014, closing a stake of 10,516 shares — an estimated $903K sold.

Harris Associates first reported a position in CELG in Q2 2013 and held it in 5 quarters. The position peaked at $903K in Q2 2014. 1,031 funds tracked by Wall St. Rank hold CELG as of Q3 2014.

Harris Associates reported no remaining Celgene Corp position as of Q3 2014 after selling out during the quarter.
Harris Associates sold 10,516 Celgene Corp shares in Q3 2014, an estimated $903K.
Harris Associates first reported a position in Celgene Corp in Q2 2013 and held it in 5 quarters.
Harris Associates's Celgene Corp position peaked at $903K in Q2 2014.
1,031 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2014.

Based on Harris Associates's 13F filing for Q3 2014, filed 12 Nov 2014.